Search Results - "Etienne, P. L."

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results by Aparicio, T., Bouché, O., Taieb, J., Maillard, E., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Paillaud, E., Retornaz, F., François, E., Bedenne, L.

“…Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but…”
Get full text

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer by Bascoul-Mollevi, C., Gourgou, S., Galais, M.-P., Raoul, J.-L., Bouché, O., Douillard, J.-Y., Adenis, A., Etienne, P.-L., Juzyna, B., Bedenne, L., Conroy, T.

“…A recent prospective randomised trial did not reveal significant differences in median progression-free survival between two chemoradiotherapy (CRT) regimens…”
Get full text

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) by Adenis, A., Bennouna, J., Etienne, P.L., Bogart, E., Francois, E., Galais, M.P., Ben Abdelghani, M., Michel, P., Metges, J.P., Dahan, L., Conroy, T., Ghiringhelli, F., Drouillard, A., El Hajbi, F., Samalin, E., Hiret, S., Delaine-Clisant, S., Mariette, C., Penel, N., Piessen, G., Le Deley, M.C.

“…The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC). E-DIS is a discontinuation trial,…”
Get full text

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer by Aparicio, T., Bouché, O., Francois, E., Retornaz, F., Barbier, E., Taieb, J., Kirscher, S., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Bedenne, L., Paillaud, E., Zawadi, Mohamed-Ayman, Volet, Julien, Cavaglione, Gérard, Lepere, Céline, Rougier, Philippe, Zaanan, Aziz, Besson, Dominique, Fawzi, Kara Slimane, Adenis, Antoine, Gatineau-Sailliant, Gilles, Brezault, Catherine, Coriat, Romain, Tougeron, David, Hautefeuille, Vincent, Chone, Laurence, Molin, Yann, Seitz, Jean-François, Le Tallec, Véronique Jestin, Ben Abdelghani, Meher, Villing, Anne-Laure, Aouakli, Amar, Sebbagh, Virginie, Bedjaoui, Ahmed, Mitry, Emmanuel, Carola, Elisabeth, Boulat, Olivier, Queuniet, Anne-Marie, Capitain, Olivier, Jouve, Jean-Louis, Baumgaertner, Isabelle, Almaric, Françoise, Bonnetain, Franck, Subtil, Fabien

“…Older patients have frailty characteristics that impair the transposition of treatment results found in younger patients. Predictive factors are needed to help…”
Get full text

Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer by Blazeby, J.M, Conroy, T, Hammerlid, E, Fayers, P, Sezer, O, Koller, M, Arraras, J, Bottomley, A, Vickery, C.W, Etienne, P.L, Alderson, D

“…Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the…”
Get full text

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results by Aparicio, T, Bouché, O, Taieb, J, Maillard, E, Kirscher, S, Etienne, P -L, Faroux, R, Khemissa Akouz, F, El Hajbi, F, Locher, C, Rinaldi, Y, Lecomte, T, Lavau-Denes, S, Baconnier, M, Oden-Gangloff, A, Genet, D, Paillaud, E, Retornaz, F, François, E, Bedenne, L

Get full text

Pregnancies after breast cancer: Is there a real need for fertility preservation? Results from the ARTEMIS cohort of 60 young patients by Martin-Babau, J., Toudic-Emily, F., Boivin, A.-H., Burban-Provost, P., Vie, B., Etienne, P.-L., Lamezec, B., Le Fur, E., Vincent, A., Besson, D., Hardy-Bessard, A.-C.

Get full text

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study by de Gramont, A, Bosset, J F, Milan, C, Rougier, P, Bouché, O, Etienne, P L, Morvan, F, Louvet, C, Guillot, T, François, E, Bedenne, L

“…This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule…”
Get more information

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial by Pénichoux, J, Michiels, S, Bouché, O, Etienne, P.-L, Texereau, P, Auby, D, Rougier, P, Ducreux, M, Pignon, J.-P

“…Abstract The FFCD 2000–05 randomised trial included 410 patients with advanced colorectal cancer and compared a sequential arm S treated with 5-fluorouracil…”
Get full text

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer by Conroy, T, Yataghène, Y, Etienne, P L, Michel, P, Senellart, H, Raoul, J L, Mineur, L, Rives, M, Mirabel, X, Lamezec, B, Rio, E, Le Prisé, E, Peiffert, D, Adenis, A

“…Background: Concurrent chemoradiotherapy is a valuable treatment option for localised oesophageal cancer (EC), but improvement is still needed. A randomised…”
Get full text

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial by Bachet, J.B., Lucidarme, O., Levache, C.B., Barbier, E., Raoul, J.L., Lecomte, T., Desauw, C., Brocard, F., Pernot, S., Breysacher, G., Lagasse, J.P., Di Fiore, F., Etienne, P.L., Dupuis, O.J.M., Aleba, A., Lepage, C., Taieb, J., Dahan, L., Auby, D., Khemissa, F., Ghiringhelli, F., Nguyen, S., Bedjaoui, A., Terrebonne, E., Thaury, J., Baconnier, M.

“…The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of…”
Get full text

Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France by Lombard-Bohas, C, Mitry, E, O'Toole, D, Louvet, C, Pillon, D, Cadiot, G, Borson-Chazot, F, Aparicio, T, Ducreux, M, Lecomte, T, Etienne, P L, Cacheux, W, Legoux, J L, Seitz, J F, Ruszniewski, P, Chayvialle, J A, Rougier, P

“…The prevalence, clinical profiles and management of gastroenteropancreatic endocrine tumours (GEP) in France are not known. From August 1, 2001 to September 1,…”
Get more information

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients by Ducreux, M., Mitry, E., Ould-Kaci, M., Boige, V., Seitz, J. F., Bugat, R., Breau, J. L., Bouché, O., Etienne, P. L., Tigaud, J. M., Morvan, F., Cvitkovic, E., Rougier, P.

“…Background: A randomized phase II, open-label multicenter study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an…”
Get full text

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival by Conroy, T., Etienne, P.-L., Adenis, A., Ducreux, M., Paillot, B., Oliveira, J., Seitz, J.-F., Francois, E., Van Cutsem, E., Wagener, D. J. T., Kohser, F., Daamen, S., Praet, M., Gorlia, T., Baron, B., Wils, J.

“…Background Vinorelbine and cisplatin are active against squamous cell oesophageal carcinoma. The purpose of this phase II study was to evaluate the efficacy…”
Get full text

Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer by Jassem, J., Kosmidis, P., Ramlau, R., Zarogoulidis, K., Novakova, L., Breton, J., Etienne, P.-L., Seebacher, C., Grivaux, M., Ojala, A., Aubert, D., Lefresne, F.

“…Background: A phase II trial of alternating i.v. and oral vinorelbine in combination with cisplatin was designed to determine the response rate, safety…”
Get full text

A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus by Le Prise, E, Etienne, P L, Meunier, B, Maddern, G, Ben Hassel, M, Gedouin, D, Boutin, D, Campion, J P, Launois, B

“…Despite well-established surgical approaches, the prognosis for patients with squamous cell carcinoma of the esophagus remains dismal. To assess the benefit of…”
Get more information

Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20 by Aparicio, T., Bouché, O., Francois, E., Maillard, E., Kirscher, S., Taieb, J., Etienne, P.-L., Faroux, R., Khemissa Akouz, F., El Hajbi, F., Locher, C., Rinaldi, Y., Lecomte, T., Lavau-Denes, S., Baconnier, M., Oden-Gangloff, A., Genet, D., Paillaud, E., Retornaz, F., Bedenne, L.

Get full text

Combined radiochemotherapy for postoperative recurrence of oesophageal cancer by Raoul, J L, Le Prisé, E, Meunier, B, Julienne, V, Etienne, P L, Gosselin, M, Launois, B

“…Postoperative recurrences are common after resection for oesophageal cancer. From January 1986 to September 1993 31 patients (30 males, one female, mean (SD)…”
Get full text

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial by Touchefeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J. M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P. L., Phelip, J. M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O.

“…Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and…”
Get full text

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer by Namer, M, Soler-Michel, P, Turpin, F, Chinet-Charrot, P, de Gislain, C, Pouillart, P, Delozier, T, Luporsi, E, Etienne, P.L, Schraub, S, Eymard, J.C, Serin, D, Ganem, G, Calais, G, Maillart, P, Colin, P, Trillet-Lenoir, V, Prevost, G, Tigaud, D, Clavère, P, Marti, P, Romieu, G, Wendling, J.L

“…This comparative phase III trial of mitoxantrone+vinorelbine (MV) versus 5-fluorouracil+cyclophosphamide+either doxorubicin or epirubicin (FAC/FEC) in the…”
Get full text